SNDX Q1 2017 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$305,000+0.0% YoY

Gross Profit

$305,000100.0% margin

Operating Income

-$13M-4320.3% margin

Net Income

-$13M-4252.8% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$98M

Total Liabilities

$25M

Stockholders' Equity

$73M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$305,000	$305,000	+0.0%
Gross Profit	$305,000	$305,000	+0.0%
Operating Income	-$13M	-$9M	-50.5%
Net Income	-$13M	-$10M	-25.6%